Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batroxobin Injection Post-marketing Safety Study in Sudden Sensorineural Hearing Loss
CTR20260128Phase 4Active
- Sponsor
- Beijing Tobishi Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of batroxobin in brain infarction, peripheral artery occlusion (PAD), deep vein thrombosis (DVT), pulmonary embolism (PE), peripheral vascular disease (PVD), sponsored by Beijing Tobishi Pharmaceutical Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
batroxobin
03
Conditions
brain infarctionperipheral artery occlusion (PAD)deep vein thrombosis (DVT)pulmonary embolism (PE)peripheral vascular disease (PVD)
Beyond the preview
Go deeper on CTR20260128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260128.